Determination of the impact of melanoma surgical timing on survival using the National Cancer Database

Siegel, 2016, Cancer statistics, 2016, CA Cancer J Clin, 66, 7, 10.3322/caac.21332 American Cancer Society, 2016 1975 Nikolaou, 2014, Emerging trends in the epidemiology of melanoma, Br J Dermatol, 170, 11, 10.1111/bjd.12492 Breitbart, 2012, Systematic skin cancer screening in northern Germany, J Am Acad Dermatol, 66, 201, 10.1016/j.jaad.2010.11.016 Morton, 2014, Final trial report of sentinel-node biopsy versus nodal observation in melanoma, N Engl J Med, 370, 599, 10.1056/NEJMoa1310460 Murphy, 2016, Survival impact of increasing time to treatment initiation for patients with head and neck cancer in the United States, J Clin Oncol, 34, 169, 10.1200/JCO.2015.61.5906 Bleicher, 2016, Time to surgery and breast cancer survival in the United States, JAMA Oncol, 2, 330, 10.1001/jamaoncol.2015.4508 McKenna, 2002, The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival, Br J Dermatol, 147, 48, 10.1046/j.1365-2133.2002.04815.x Baade, 2006, The relationship between melanoma thickness and time to diagnosis in a large population-based study, Arch Dermatol, 142, 1422, 10.1001/archderm.142.11.1422 Torring, 2013, Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care, Eur J Cancer, 49, 2187, 10.1016/j.ejca.2013.01.025 Hajdarevic, 2014, Health-care delay in malignant melanoma: various pathways to diagnosis and treatment, Dermatol Res Pract, 2014, 294287, 10.1155/2014/294287 Garbe, 2016, Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline—update 2016, Eur J Cancer, 63, 201, 10.1016/j.ejca.2016.05.005 Bilimoria, 2008, The National Cancer Data Base: a powerful initiative to improve cancer care in the United States, Ann Surg Oncol, 15, 683, 10.1245/s10434-007-9747-3 Neal, 2015, Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review, Br J Cancer, 112, S92, 10.1038/bjc.2015.48 Survival Quan, 2011, Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries, Am J Epidemiol, 173, 676, 10.1093/aje/kwq433 Carpenter, 2008, Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome?, Am J Surg, 196, 834, 10.1016/j.amjsurg.2008.07.044 Parrett, 2012, The effect of delay time between primary melanoma biopsy and sentinel lymph node dissection on sentinel node status, recurrence, and survival, Melanoma Res, 22, 386, 10.1097/CMR.0b013e32835861f6 Pacifico, 2007, The UK government two-week rule and its impact on melanoma prognosis: an evidence-based study, Ann R Coll Surg Engl, 89, 609, 10.1308/003588407X205459 Israel Cancer Association Haaretz Watts, 2015, Specialized surveillance for individuals at high risk for melanoma: a cost analysis of a high-risk clinic, JAMA Dermatol, 151, 178, 10.1001/jamadermatol.2014.1952 Sella, 2015, Incidence trends of keratinocytic skin cancers and melanoma in Israel 2006-11, Br J Dermatol, 172, 202, 10.1111/bjd.13213 McKenna, 2004, A comparison of dermatologists', surgeons' and general practitioners' surgical management of cutaneous melanoma, Br J Dermatol, 151, 636, 10.1111/j.1365-2133.2004.06065.x DeFazio, 2010, Variation in the depth of excision of melanoma: a survey of US physicians, Arch Dermatol, 146, 995, 10.1001/archdermatol.2010.156 Corbo, 2012, Comparison of dermatologists' and nondermatologists' diagnostic accuracy for malignant melanoma, J Cutan Med Surg, 16, 272, 10.1177/120347541201600410 Martinka, 2016, Clinical recognition of melanoma in dermatologists and nondermatologists, J Cutan Med Surg, 20, 532, 10.1177/1203475415623513 Charles, 2005, Variation in the diagnosis, treatment, and management of melanoma in situ: a survey of US dermatologists, Arch Dermatol, 141, 723, 10.1001/archderm.141.6.723 van Zeijl, 2017, (Neo)adjuvant systemic therapy for melanoma, Eur J Surg Oncol, 43, 534, 10.1016/j.ejso.2016.07.001 Davar, 2013, Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach, Clin Dermatol, 31, 237, 10.1016/j.clindermatol.2012.08.012 Moschos, 2006, Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses, J Clin Oncol, 24, 3164, 10.1200/JCO.2005.05.2498 Raigani, 2017, The role of surgery for melanoma in an era of effective systemic therapy, Curr Oncol Rep, 19, 17, 10.1007/s11912-017-0575-8